ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF

The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect o...

Full description

Saved in:
Bibliographic Details
Main Authors KRYSTEK, JR. STANLEY RICHARD, SCHNEEWEIS, LUMELLE, YAMNIUK, AARON PAUL, EWING, WILLIAM R, PINCKNEY, JASON ROBERT, AN, YONGMI, DILGER, ANDREW KARL, TERRAGNI, CHRISTINA, SHERIFF, STEVEN, LUETTGEN, JOSEPH M, RAKESTRAW, GINGER CHAO, KISH, KEVIN
Format Patent
LanguageEnglish
French
Published 14.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample. La présente invention concerne de nouveaux peptides de liaison à l'antigène, tels qu'un anticorps ou qu'un fragment d'anticorps, qui se lient spécifiquement à des inhibiteurs de FXIa sélectifs et/ou à des inhibiteurs doubles de FXIa, ainsi que de la kallicréine plasmatique. La présente invention concerne en outre des méthodes de réduction de l'effet antithrombotique d'inhibiteurs de FXIa par l'administration à un sujet d'une dose pharmaceutiquement efficace des peptides de liaison à l'antigène de la présente invention. De plus, la présente invention concerne des réactifs de détection et des méthodes de détection du niveau des inhibiteurs de FXIa dans un échantillon biologique.
AbstractList The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample. La présente invention concerne de nouveaux peptides de liaison à l'antigène, tels qu'un anticorps ou qu'un fragment d'anticorps, qui se lient spécifiquement à des inhibiteurs de FXIa sélectifs et/ou à des inhibiteurs doubles de FXIa, ainsi que de la kallicréine plasmatique. La présente invention concerne en outre des méthodes de réduction de l'effet antithrombotique d'inhibiteurs de FXIa par l'administration à un sujet d'une dose pharmaceutiquement efficace des peptides de liaison à l'antigène de la présente invention. De plus, la présente invention concerne des réactifs de détection et des méthodes de détection du niveau des inhibiteurs de FXIa dans un échantillon biologique.
Author LUETTGEN, JOSEPH M
EWING, WILLIAM R
RAKESTRAW, GINGER CHAO
TERRAGNI, CHRISTINA
SCHNEEWEIS, LUMELLE
PINCKNEY, JASON ROBERT
YAMNIUK, AARON PAUL
AN, YONGMI
DILGER, ANDREW KARL
SHERIFF, STEVEN
KISH, KEVIN
KRYSTEK, JR. STANLEY RICHARD
Author_xml – fullname: KRYSTEK, JR. STANLEY RICHARD
– fullname: SCHNEEWEIS, LUMELLE
– fullname: YAMNIUK, AARON PAUL
– fullname: EWING, WILLIAM R
– fullname: PINCKNEY, JASON ROBERT
– fullname: AN, YONGMI
– fullname: DILGER, ANDREW KARL
– fullname: TERRAGNI, CHRISTINA
– fullname: SHERIFF, STEVEN
– fullname: LUETTGEN, JOSEPH M
– fullname: RAKESTRAW, GINGER CHAO
– fullname: KISH, KEVIN
BookMark eNrjYmDJy89L5WQIcvQL8XTyd_F0DVZw9HNRAHHdXf0UnDz9XDz93BUCXANCPF2Akm7-QQpujs4hQCrC01HB08_D08kTyINoCw0GKgnxcA1y9XfjYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GRgYmpqZGjobGRCgBAHneMH4
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ANTICORPS ET PEPTIDES DE LIAISON A L'ANTIGENE POUR DES INHIBITEURS DU FACTEUR XIA ET LEURS UTILISATIONS
ExternalDocumentID CA3204552A1
GroupedDBID EVB
ID FETCH-epo_espacenet_CA3204552A13
IEDL.DBID EVB
IngestDate Fri Aug 30 05:41:43 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CA3204552A13
Notes Application Number: CA20223204552
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220714&DB=EPODOC&CC=CA&NR=3204552A1
ParticipantIDs epo_espacenet_CA3204552A1
PublicationCentury 2000
PublicationDate 20220714
PublicationDateYYYYMMDD 2022-07-14
PublicationDate_xml – month: 07
  year: 2022
  text: 20220714
  day: 14
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies BRISTOL-MYERS SQUIBB COMPANY
JANSSEN PHARMACEUTICA NV
RelatedCompanies_xml – name: JANSSEN PHARMACEUTICA NV
– name: BRISTOL-MYERS SQUIBB COMPANY
Score 3.407297
Snippet The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220714&DB=EPODOC&locale=&CC=CA&NR=3204552A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLamgYAbDBDjpRxQbxVb13bjUKE0SdcgLa2mDu029XXYpZtYEX8fp3vABU55WIkSS3bsxP4C8DQcDTQqmmXmQ8c17X5WmGnhpGZPI5NoyE-r0NnIE-WGM_tt7sxbsNznwjQ4oV8NOCJKVI7yXjf6ev1zicWb2MrNc7bErtVrkHjc2HnHlqXzcQzueyKOeMQMxjxGDTX1Bhp23bEoOkpHaEUPtTCId18npax_nyjBORzHOFlVX0CrrDpwyvYfr3XgZLJ778bqTvQ2lzClKpF-pM03QhUnujkWivhScanGJBZxIjkS0a0jAWUJFnNJiVSh9CW2tsNmqD9JEoqpiIIrIIFIWGji4hYHRiwYPWxjcA3talWVN0DQpMt67qi085Fjp0Wa5i6agf3yxcr76B85Xej-Oc3tP7Q7ONMc3cam3kO7_vgsH_AErrPHhnff1IKBqQ
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFH8haMSbokb87MHstsjGNvCwmK3bWBW6hRTDjezrwGUQmfHf93UO9KKn9rVp077k9X2071eAh-FoIFHRdDUbmpZqaGmuJrmZqH2JTCIhP_VcZiNPuRXOjZeFuWjBapcLU-OEftbgiChRGcp7VZ_Xm58glle_rdw-pitsWj8HwvaUxjvWdZmPo3iu7ceRF1GFUps6Cp_ZAwm7buoOOkoHaGEPpTD4b65MStn81ijBCRzGOFlZnUKrKLvQobuP17pwNG3uu7HaiN72DGYOF8yNpPlGHO4RSY59TlzGPcbHJPZjwTzsRLeOBA4VWCyYQxgPmcuQ-h42x_OTiNCf-VFwDiTwBQ1VXNxyz4gldfbbGFxAu1yXxSUQNOnSvjUqjGxkGkmeJJmFZqBWPOmZhv6R2YPen9Nc_dN3D51QTCfLCeOv13AsuSuDmppxA-3q_aO4RW1cpXc1H78AFeqEoA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTIBODIES+AND+ANTIGEN+BINDING+PEPTIDES+FOR+FACTOR+XIA+INHIBITORS+AND+USES+THEREOF&rft.inventor=KRYSTEK%2C+JR.+STANLEY+RICHARD&rft.inventor=SCHNEEWEIS%2C+LUMELLE&rft.inventor=YAMNIUK%2C+AARON+PAUL&rft.inventor=EWING%2C+WILLIAM+R&rft.inventor=PINCKNEY%2C+JASON+ROBERT&rft.inventor=AN%2C+YONGMI&rft.inventor=DILGER%2C+ANDREW+KARL&rft.inventor=TERRAGNI%2C+CHRISTINA&rft.inventor=SHERIFF%2C+STEVEN&rft.inventor=LUETTGEN%2C+JOSEPH+M&rft.inventor=RAKESTRAW%2C+GINGER+CHAO&rft.inventor=KISH%2C+KEVIN&rft.date=2022-07-14&rft.externalDBID=A1&rft.externalDocID=CA3204552A1